Clinical Trial Update: Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of eculizumab to prevent antibody-mediated rejection in living donor kidney transplant recipients requiring desensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Antibody Mediated Rejection | Phase 2 | Status: TERMINATED | Results posted: 2017-04-19